Quotes: MENA   Enter Symbol: NewsLetter: Search: advanced

Experts in Africa cautious on potential malaria vaccine  Join our daily free Newsletter

MENAFN - AFP - 08/10/2013
No. of Ratings : 0
Add to Mixx!

(MENAFN - AFP) Experts in Africa, the continent worst-hit by malaria, reacted with optimism but also caution on Tuesday to news that the first vaccine against the killer disease may soon reach the market.

GlaxoSmithKline said it was seeking approval for a prototype vaccine that reduced the risk of malaria by almost half among children aged between five and 17 months, and by around a quarter among infants aged between six and 12 weeks.

"This is the first vaccine against malaria," Sophie Biernaux, a malaria vaccine leader at GSK, told AFP in Durban.

If the British drugmaker's application is successful, the vaccine could be rolled out within two years.

The mosquito-borne disease kills an estimated 660,000 people each year, 90 percent of them in Africa, with the majority being children under five.

"This is great hope for Africa," Nilton Saraivo, a manager of Angola's national anti-malaria programme, told AFP.

But others were more cautious.

In Gabon, one of the countries where clinical trials were conducted, researcher Bertrand Lell said the vaccine's efficacy "is not very large" compared to vaccines such as the one against polio.

"But given the prevalence of malaria in Africa, you can imagine the impact it will have on people if the mortality rate is down 50 percent," said Lell, of the Lambarene Centre for Medical Research.

In the Democratic Republic of Congo -- which has the world's second-highest malaria death rate after Nigeria -- SANRU, an organisation that distributes mosquito nets to fight malaria, said it was too early to declare victory.

It noted that the vaccine did not offer a complete shield, although trials -- including assessment of a booster shot -- are ongoing.

"This is good news as long as the vaccine shows a required level of efficacy," said John Gikapa, technical advisor to SANRU.

The research was carried out at 11 centres in seven African countries, covering more than 15,000 infants and children.

GSK said it would now file an application to the European Medicines Agency (EMA) under a process aimed at marketing new drugs for poorer countries.

The European medications watchdog will then give a "scientific opinion" on the vaccine's safety and efficacy.

This opens the way for it to be considered by the World Health Organisation (WHO), which in turn can fast-track its licensing in individual countries in Africa.

The vaccine -- called RTS,S -- is a frontrunner in the race to develop the first immunisation for malaria.

The results for the Phase III trial were unveiled Tuesday at a conference in South Africa.

They are sure to raise as many questions as answers.

As well as offering less protection for very small children, the vaccine's effectiveness declined over time, data showed.

"There are a number of possible hypotheses for these differences" in effectiveness, said Lucas Otieno of the Kenya Medical Research Institute, one of the principal investigators in the trial.

The theories include possible interference with the vaccine by maternal antibodies and the impact of other vaccines administered around the same time, he said.

'Any progress welcome'

Experts are also wary about the logistics of administering the vaccine in Africa, where the people most at risk often live in poverty-stricken and difficult-to-access places.

Just getting drugs to where they are needed can be a headache, requiring proper handling in hot, humid environments and secure storage in countries where theft or corruption may be rampant.

"Any progress on fighting malaria is very welcome, and this vaccine could be another important weapon in our armoury," said Martin de Smet, a malaria specialist with Doctors Without Borders (MSF).

"Delivering injection-based vaccines in the kind of environments where malaria is prominent is also hugely challenging -- even for treatments that are 100-percent effective," he said.

"Locations are traditionally remote, with people having to walk for days to get to a health facility, and often require refrigeration."

GSK said if it gets the green light, the vaccine would probably be distributed through agencies such as the United Nations Children's Fund and the GAVI Alliance, a public-private health partnership.

The price would cover the cost of manufacturing plus a margin of five percent which would be ploughed into research for next-generation vaccines, a GSK spokesman said.



  MENA News Headlines
 Oct 22 2016 - EU regrets withdrawal of South Africa from ICCKuwait News Agency (KUNA)
(MENAFN - Kuwait News Agency (KUNA)) BRUSSELS, Oct 22 (KUNA) -- The European Union has expressed its "deep regrets "over South Africa's decision to initiate its withdrawal from the International ...

 Oct 22 2016 - Kuwait- KUNA main news for Saturday, Oct 22, 2016Kuwait News Agency (KUNA)
(MENAFN - Kuwait News Agency (KUNA)) Local: KUWAIT -- With attendance of the visiting Queen Silvia of Sweden, Information Minister and Minister of State for Youth Affairs Sheikh Salman ...

 Oct 22 2016 - Swiss NGO honors Kuwaiti-based institute for global effortsKuwait News Agency (KUNA)
(MENAFN - Kuwait News Agency (KUNA)) By Nawab Khan BRUSSELS, Oct 22 (KUNA) -- The Arab Planning Institute (API), based in Kuwait, has been awarded the prestigious Gold Medal by the Crans Montana ...

 Oct 22 2016 - Kuwait- Info. Min. decides: Ban on primaries, reputation smearing, financial incentivesKuwait News Agency (KUNA)
(MENAFN - Kuwait News Agency (KUNA)) KUWAIT, Oct 20 (KUNA) -- The Minister of Information has issued a Ministerial Resolution stipulating total ban on primaries, tit-for-tat mudslinging among ...

 Oct 22 2016 - Boursa Kuwait ended last week with mixed performanceKuwait News Agency (KUNA)
(MENAFN - Kuwait News Agency (KUNA)) KUWAIT, Oct 22 (KUNA) -- Boursa Kuwait ended last week with mixed performance, as the Price Index closed at 5,321.46 points, down by 0.12 percent from the week ...

 Oct 22 2016 - US Secretary of Defense to meet with Iraqi Prime MinisterKuwait News Agency (KUNA)
(MENAFN - Kuwait News Agency (KUNA)) BAGHDAD, Oct 22 (KUNA) -- US Secretary of Defense Ashton Carter arrived in Baghdad on Saturday to meet with Iraqi Prime Minister Dr. Haidar Al-Abadi along with a ...

 Oct 22 2016 - Kuwait- Info. Min. launches campaign for covering legislative electionsKuwait News Agency (KUNA)
(MENAFN - Kuwait News Agency (KUNA)) KUWAIT, Oct 22 (KUNA) -- Minister of Information and Minister of State for Youth Affairs Sheikh Salman Sabah Salem Al-Sabah announced on Saturday the launching of ...

 Oct 22 2016 - Nizzolo wins Stage 1 of Abu Dhabi TourKhaleej Times
(MENAFN - Khaleej Times) Reigning Italian champion Giacomo Nizzolo (Trek - Segafredo) won Stage 1 of the second Abu Dhabi Tour as he outsprinted John Degenkolb (Team Giant - Alpecin) and race ...

 Oct 22 2016 - UAE- Two jailed for sharing indecent video of disabled manKhaleej Times
(MENAFN - Khaleej Times) Two Arab nationals were sentenced to three months in jail by the Sharjah court for capturing photographs and videos of a mentally-retarded man in an indecent manner and ...

 Oct 22 2016 - Kuwait FM delivers lecture at Atlantic CouncilKuwait News Agency (KUNA)
(MENAFN - Kuwait News Agency (KUNA)) WASHINGTON, Oct 21 (KUNA) -- Kuwait's First Deputy Prime Minister and Foreign Minister Sheikh Sabah Khaled Al-Hamad Al-Sabah delivered a lecture at the Atlantic ...





Middle East North Africa - Financial Network

MENAFN News Market Data Countries Tools Section  

Middle East North Africa - Financial Network

Main News
News By Industry
News By Country

Search News
Market Indices
Quotes & Charts

Global Indices
Arab Indices


Oil & Energy

Currencies Cross Rates
Currencies Updates
Currency Converter

USA Stocks
Arab Stocks

Saudi Arabia 

Economic Calendar
Financial Glossary

Financial Calculators

RSS Feeds [XML]

Corporate Monitor


Real Estate
Submit Your Property

Arab Research
Buy a Research

Press Releases
Submit your PR

Join Newsletters

© 2014 menafn.com All Rights Reserved.  Terms of Service | Privacy Policy | Contact Us | Advertise | About MENAFN | Career Opportunities | Feedback | Help